These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 30152192

  • 1. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
    Cho DY, Zhang S, Lazrak A, Grayson JW, Peña Garcia JA, Skinner DF, Lim DJ, Mackey C, Banks C, Matalon S, Woodworth BA.
    Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
    [Abstract] [Full Text] [Related]

  • 2. Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency.
    Woodworth BA.
    Laryngoscope; 2015 Oct; 125 Suppl 7(0 7):S1-S13. PubMed ID: 25946147
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    Liu J, Berg AP, Wang Y, Jantarajit W, Sutcliffe KJ, Stevens EB, Cao L, Pregel MJ, Sheppard DN.
    Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
    [Abstract] [Full Text] [Related]

  • 9. The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
    Raju SV, Lin VY, Liu L, McNicholas CM, Karki S, Sloane PA, Tang L, Jackson PL, Wang W, Wilson L, Macon KJ, Mazur M, Kappes JC, DeLucas LJ, Barnes S, Kirk K, Tearney GJ, Rowe SM.
    Am J Respir Cell Mol Biol; 2017 Jan; 56(1):99-108. PubMed ID: 27585394
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ivacaftor potentiation of multiple CFTR channels with gating mutations.
    Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP, Urrutia A, Joubran J, Seepersaud S, Sussky K, Hoffman BJ, Van Goor F.
    J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L, D'Oria S, Favia M, Castellani S, Santostasi T, Polizzi AM, Mariggiò MA, Gallo C, Casavola V, Montemurro P, Leonetti G, Manca A, Conese M.
    Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
    [Abstract] [Full Text] [Related]

  • 15. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
    Mutyam V, Sharma J, Li Y, Peng N, Chen J, Tang LP, Falk Libby E, Singh AK, Conrath K, Rowe SM.
    Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N.
    Vreede CL, Berkhout MC, Sprij AJ, Fokkens WJ, Heijerman HG.
    J Cyst Fibros; 2015 May; 14(3):412-3. PubMed ID: 25169789
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.